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Increased age has a negative impact on 
human cancer survival and directly cor-
relates with increased incidence, malig-
nancy and treatment resistance. However, 
little is known about the age-related 
mechanisms that impact cancer malig-
nancy. Recent findings indicate that can-
cer can originate from early progenitors/
stem cells where oncogene can impose a 
specific tumoral fate.1 Which role does age 
play here? There are many evidences indi-
cating that aging has a clear impact both 
in the numbers and in the functionality 
of stem cells.2-4 Therefore, any impact that 
age might have on the target cell-of-origin 
population may reflect in the characteris-
tics of the cancer disease.
Investigating how age affects cancer 
development is crucial for understanding 
the process of disease development and 
to design prophylactic therapies. A major 
obstacle to elucidate the in vivo contribu-
tion of age to the development and evo-
lution of cancer is the lack of appropriate 
mouse models where precise control of the 
timing of oncogene expression is possible. 
Recent studies of our group have taken 
advantage of a conditional transgenic 
mouse model of BCR-ABLp190-driven 
B-cell acute lymphoblastic leukemia 
(B-ALL) to evaluate the impact of age-
related mechanisms in B-ALL malig-
nancy.5 First, in order to clarify the direct 
impact of the age of the surrounding non-
cancerous cells on the survival of BCR-
ABL+ leukemic cells, the same number of 
B-ALL cells were injected intravenously 
into syngenic host mice of 4 or 20 mo 
of age. We found that there were no dif-
ferences in survival between young and 
old recipient mice, therefore suggesting 
that the host age (that is, the age of the 
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non-leukemic cellular environment) does 
not influence BCR-ABL+ B-ALL malig-
nancy. There is a great lack of knowledge 
about the relationship between the age of 
the target cell and the genesis of cancer. 
Therefore, we further examined how the 
age of target cell impacts on the BCR-
ABL oncogene-mediated reprogramming. 
To that end, we have taken advantage 
of the doxycline-controlled transgenic 
CombitTA-BCR-ABLp190 mouse line, 
to induce the expression of the leukemia-
triggering oncogene in mice of differ-
ent ages. We found that the malignancy 
of the induced B-ALL increases with the 
age of the normal progenitors from which 
the disease arises. Leukaemias originat-
ing from older progenitors present a more 
aggressive phenotype, and have a much 
faster evolution than leukemias initiat-
ing from young progenitors. Our results 
also imply that, to a great extent, disease 
evolution is programmed from the begin-
ning, since the starting cell determines 
the aggressiveness of the phenotype; also, 
our data indicate that the decline of the 
immune response with age is not respon-
sible for the increased development or 
aggressiveness of the tumors in the elderly, 
although these findings do not exclude 
that the number of the appropriate target 
cells available for transformation should 
be taken into account.6 Nevertheless, 
this finding is consistent with the previ-
ous observation indicating that the host 
age does not influence BCR-ABL+ ALLs 
malignancy. Altogether, these findings 
provide the first in vivo experimental 
evidence, using a conditional transgenic 
mouse model, showing that an increase 
in the age at which transformation occurs 
has a direct impact in the malignant 
potential of cancer cells. This is in agree-
ment with clinical observations showing 
that age-related cell intrinsic factors may 
play a leading role in the impact of age on 
B-ALL malignancy.7
Independently of our work, Henry et 
al. began their studies by looking at the 
effect of BCR-ABL in aging-associated 
leukemogenesis by using a retroviral trans-
duction system.8 They found that aged 
B-cell progenitors present a reduced fit-
ness due to impaired signaling machinery 
and that, since the oncogene compensates 
in part the need for kinase signaling, its 
expression promotes the positive selection 
of BCR-ABL+ cells.8
In spite of the opposite starting points 
of these two studies, both of them come 
to a remarkably consistent conclusion: 
the age of the target cell influences leu-
kemogenesis. On the other hand, while 
Henry et al. showed that both cell- 
intrinsic and extrinsic factors influence 
the biology of the BCR-ABL+ malignancy, 
we found that the main drivers of the 
BCR-ABL+ malignancies are qualitative 
and/or quantitative characteristics of the 
target cells. Moreover, the key aspect of 
our experimental approach is that BCR-
ABL is not activated until after trans-
plantation and, therefore, conveniently 
bypasses doubts over required exposures 
for the natural disease and age-associated 
alterations in the host tissue microenvi-
ronment (Fig. 1). The major questions 
that arise in light of these findings are 
how oncogene reprogramming impacts 
on the age of target cell,9,10 and what are 
the qualitative and/or quantitative fig-
ures that make aged stem/progenitor tar-
get cells more vulnerable to malignancy. 
Mouse models of cancer where precise 
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control of the timing of the oncogene 
exposure is possible will be instrumen-
tal to address these and other questions 
to understand the complexity of age- 
associated cancers.
Figure 1. Plausible mechanisms for oncogene-mediated transformation of aged target stem/progenitor cells. Cancer gene overexpression results in 
the formation of cancer stem cells, which then spontaneously give rise to more stable, differentiated state(s). aged target cells are more sensitive to 
cancer transformation than young target cells, because of still unknown qualitative and/or quantitative figures that make aged stem/progenitor target 
cells more vulnerable to malignancy. Generation of cancer cells from young target cells, on the other hand, requires prolonged overexpression of the 
same cancer genes.
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